MA49278A - Oligonucléotides antisens pour moduler l'expression de htra1 - Google Patents
Oligonucléotides antisens pour moduler l'expression de htra1Info
- Publication number
- MA49278A MA49278A MA049278A MA49278A MA49278A MA 49278 A MA49278 A MA 49278A MA 049278 A MA049278 A MA 049278A MA 49278 A MA49278 A MA 49278A MA 49278 A MA49278 A MA 49278A
- Authority
- MA
- Morocco
- Prior art keywords
- antisen
- htra1
- oligonucleotides
- modulate
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21108—HtrA2 peptidase (3.4.21.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173964 | 2017-06-01 | ||
EP17209407 | 2017-12-21 | ||
EP17209535 | 2017-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49278A true MA49278A (fr) | 2020-04-08 |
Family
ID=62245334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049278A MA49278A (fr) | 2017-06-01 | 2018-05-30 | Oligonucléotides antisens pour moduler l'expression de htra1 |
Country Status (19)
Country | Link |
---|---|
US (3) | US20190055564A1 (fr) |
EP (1) | EP3630976A1 (fr) |
JP (1) | JP7169995B2 (fr) |
KR (1) | KR20200015608A (fr) |
CN (1) | CN110691849A (fr) |
AU (1) | AU2018277219A1 (fr) |
BR (1) | BR112019025290A2 (fr) |
CA (1) | CA3062590A1 (fr) |
CL (1) | CL2019003337A1 (fr) |
CO (1) | CO2019013317A2 (fr) |
CR (1) | CR20190543A (fr) |
IL (1) | IL271039A (fr) |
MA (1) | MA49278A (fr) |
MX (1) | MX2019014187A (fr) |
PE (1) | PE20191845A1 (fr) |
PH (1) | PH12019502636A1 (fr) |
RU (1) | RU2019143004A (fr) |
TW (1) | TW201907008A (fr) |
WO (1) | WO2018220034A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180606A (es) | 2016-07-01 | 2019-02-14 | Hoffmann La Roche | Oligonucleótidos antisentido para modular la expresión de htra1 |
JP7317029B2 (ja) | 2018-02-12 | 2023-07-28 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | 修飾化合物及びその使用 |
WO2022092326A1 (fr) * | 2020-10-30 | 2022-05-05 | 英彰 原 | Modulateur de gdf15 destiné à être utilisé dans l'inhibition de la fibrose des tissus oculaires |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
IL135000A0 (en) | 1997-09-12 | 2001-05-20 | Exiqon As | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
AU5290499A (en) * | 1998-08-03 | 2000-02-28 | Novartis Ag | Human htra serine protease |
TR200604211T1 (tr) | 1999-02-12 | 2007-02-21 | Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited | Yeni nükleosid ve oligonükleotid analoglarıYeni nükleosid ve oligonükleotid analogları |
US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
DK3222722T3 (da) | 2002-11-18 | 2019-06-17 | Roche Innovation Ct Copenhagen As | Antisense-design |
EP1888083B1 (fr) * | 2005-05-24 | 2011-12-28 | Isis Pharmaceuticals, Inc. | Compositions et utilisations dans la lmw-ptpase |
WO2007031091A2 (fr) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Composes antagonistes d'arn de modulation de l'expression de p21 ras |
PL1984381T3 (pl) | 2006-01-27 | 2011-03-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
WO2008013893A2 (fr) | 2006-07-26 | 2008-01-31 | Yale University | Diagnostic et traitement de la dégénérescence maculaire |
WO2008067040A2 (fr) * | 2006-10-06 | 2008-06-05 | University Of Utah Research Foundation | Procédé de détection de maladies et d'affections pathologiques de l'œil et traitement de celles-ci |
WO2008150729A2 (fr) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué |
EP2173760B2 (fr) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Analogues d'acide nucléique bicyclique carbocylique |
TW200911290A (en) * | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
EP2176280B2 (fr) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques bicycliques disubstitués en position 6 |
EP2217720A4 (fr) * | 2007-11-01 | 2010-12-08 | Univ Iowa Res Found | Analyse de lieu de rca pour estimer la sensibilité à l'amd et au mpgnii |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
WO2010036698A1 (fr) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Nucléosides alpha-l-bicycliques substitués |
EP2462153B1 (fr) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Analogues d'acides nucléiques cyclohexoses bicycliques |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
FR2965278B1 (fr) * | 2010-09-23 | 2014-10-10 | Univ Caen Basse Normandie | Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations |
CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
WO2013154798A1 (fr) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Analogues tricycliques d'acide nucléique |
US20150141320A1 (en) * | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
AU2013346767B2 (en) | 2012-11-15 | 2019-04-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
US20190284621A1 (en) * | 2016-11-11 | 2019-09-19 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
-
2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 CA CA3062590A patent/CA3062590A1/fr not_active Abandoned
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja active Active
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/fr active Pending
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/fr active Application Filing
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko unknown
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
-
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
-
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20190543A (es) | 2020-02-10 |
BR112019025290A2 (pt) | 2020-06-23 |
WO2018220034A1 (fr) | 2018-12-06 |
US20200157546A1 (en) | 2020-05-21 |
TW201907008A (zh) | 2019-02-16 |
EP3630976A1 (fr) | 2020-04-08 |
US20190055564A1 (en) | 2019-02-21 |
MX2019014187A (es) | 2020-01-27 |
CN110691849A (zh) | 2020-01-14 |
AU2018277219A1 (en) | 2019-12-19 |
PE20191845A1 (es) | 2019-12-31 |
CL2019003337A1 (es) | 2020-05-15 |
US20220042022A1 (en) | 2022-02-10 |
CO2019013317A2 (es) | 2020-01-17 |
CA3062590A1 (fr) | 2018-12-06 |
PH12019502636A1 (en) | 2020-06-08 |
JP7169995B2 (ja) | 2022-11-11 |
JP2020521491A (ja) | 2020-07-27 |
IL271039A (en) | 2020-01-30 |
RU2019143004A (ru) | 2021-07-09 |
KR20200015608A (ko) | 2020-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
DK3516060T3 (da) | Antisense-oligonukleotider til behandling af øjensygdom | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA46180A (fr) | Analogues de l'amyline | |
ZA201808291B (en) | Antisense oligonucleotides for modulating htra1 expression | |
MA53474A (fr) | Distribution de lingettes | |
MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
MA49278A (fr) | Oligonucléotides antisens pour moduler l'expression de htra1 | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
MA41271A (fr) | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 | |
MA51795A (fr) | Oligonucléotides pour moduler l'expression de tmem106b | |
FR3020758B1 (fr) | Composition pour ameliorer l'hygiene buco-dentaire | |
FR3056087B1 (fr) | Pot en porcelaine ou en ceramique pour cosmetiques | |
ITUB20153017A1 (it) | Dispositivo per l'avvolgimento di prodotti | |
ITUB20153542A1 (it) | Composizione cosmetica ad attivita' idratante | |
MA52738A (fr) | Méthodes de traitement de l'arthrite psoriasique | |
MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
MA45227A (fr) | Peptides pour le traitement de l'ostéoarthrite |